Drugs / JMKX003142
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07565441 | May → Nov 2026 expected | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07470177 | Mar → May 2026 overdue | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07463053 | Mar → May 2026 overdue | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06658964 | Nov → Dec 2024 overdue | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06344533 | Apr 2024 → Jan 2025 | — | Jemincare | Unknown | No outcome recorded |
| Phase 1 | NCT06079541 | Jul 2023 → Jul 2024 | — | Jemincare | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06949020 | Jun 2025 → Jan 2027 expected | heart failure | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06800651 | Mar 2025 → Feb 2027 expected | autosomal dominant polycystic kidney disease | Jemincare | Recruiting | No outcome recorded |
| Phase 2 | NCT06670534 | Jan 2025 → Jul 2026 overdue | — | Jemincare | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07841093 | Feb 2027 → Apr 2028 expected | — | Jemincare | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-22 | Jemincare | Regulatory 济民可信四项1类新药临床试验获批 jemincare.com ↗
JMKX003142口服片于 4 月 17 日获国家药品监督管理局批准，同意本品开展治疗常染色体显性多囊肾病的临床试验。 |
| 2023-01-10 | Jemincare | Regulatory 标题：济民可信多囊性肾病创新药获FDA批准开展临床试验 jemincare.com ↗
济民可信集团宣布，旗下子公司上海济煜医药科技有限公司（以下简称“上海济煜”）的创新化药 JMKX003142 口服片新药临床试验申请（ IND ）已获得美国 FDA 批准，同意该药物开展多囊性肾病适应症者的临床试验。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-22 | Jemincare | 济民可信四项1类新药临床试验获批 jemincare.com ↗ |
| 2023-01-10 | Jemincare | 标题：济民可信多囊性肾病创新药获FDA批准开展临床试验 jemincare.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX003142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06949020 ↗ |
| Action | Inhibit | “JMKX003142 is an arginine vasopressin（AVP）-V2R antagonist” NCT06670534 ↗ |
| Route | Oral | “JMKX003142 will be administered orally” NCT06079541 ↗ |